These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33188573)

  • 1. Walking activity in a large cohort of boys with Duchenne muscular dystrophy.
    Lott DJ; Taivassalo T; Senesac CR; Willcocks RJ; Harrington AM; Zilke K; Cunkle H; Powers C; Finanger EL; Rooney WD; Tennekoon GI; Vandenborne K
    Muscle Nerve; 2021 Feb; 63(2):192-198. PubMed ID: 33188573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy.
    Bendixen RM; Lott DJ; Senesac C; Mathur S; Vandenborne K
    Disabil Rehabil; 2014; 36(22):1918-23. PubMed ID: 24499260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy.
    Davidson ZE; Ryan MM; Kornberg AJ; Walker KZ; Truby H
    J Child Neurol; 2015 Mar; 30(3):357-63. PubMed ID: 24762862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal community walking activity in Duchenne muscular dystrophy.
    Fowler EG; Staudt LA; Heberer KR; Sienko SE; Buckon CE; Bagley AM; Sussman MD; McDonald CM
    Muscle Nerve; 2018 Mar; 57(3):401-406. PubMed ID: 28692198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
    Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boys With Duchenne Muscular Dystrophy: 1-Year Locomotor Changes in Relation to a Control Group.
    Martini J; Caromano FA; Carvalho EV; Goya PA; Hayasaka RM; Nakazune S; Fávero FM; Voos MC
    Percept Mot Skills; 2018 Feb; 125(1):40-56. PubMed ID: 29171337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring daily physical activity of upper extremity in young and adolescent boys with Duchenne muscular dystrophy: A pilot study.
    van der Geest A; Essers JMN; Bergsma A; Jansen M; de Groot IJM
    Muscle Nerve; 2020 Mar; 61(3):293-300. PubMed ID: 31742708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quadriceps muscle strength in Duchenne muscular dystrophy and effect of corticosteroid treatment.
    Merlini L; Cecconi I; Parmeggiani A; Cordelli DM; Dormi A
    Acta Myol; 2020 Dec; 39(4):200-206. PubMed ID: 33458575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy.
    Connolly AM; Zaidman CM; Golumbek PT; Cradock MM; Flanigan KM; Kuntz NL; Finkel RS; McDonald CM; Iannaccone ST; Anand P; Siener CA; Florence JM; Lowes LP; Alfano LN; Johnson LB; Nicorici A; Nelson LL; Mendell JR;
    Muscle Nerve; 2019 Jun; 59(6):650-657. PubMed ID: 30706490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related changes in appendicular lean mass in males with Duchenne muscular dystrophy: A retrospective review.
    Summer SS; Wong BL; Rutter MM; Horn PS; Tian C; Rybalsky I; Shellenbarger KC; Kalkwarf HJ
    Muscle Nerve; 2021 Feb; 63(2):231-238. PubMed ID: 33104257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.
    Arora H; Willcocks RJ; Lott DJ; Harrington AT; Senesac CR; Zilke KL; Daniels MJ; Xu D; Tennekoon GI; Finanger EL; Russman BS; Finkel RS; Triplett WT; Byrne BJ; Walter GA; Sweeney HL; Vandenborne K
    Muscle Nerve; 2018 Nov; 58(5):631-638. PubMed ID: 29742798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical Activity in Boys With Duchenne Muscular Dystrophy Is Lower and Less Demanding Compared to Healthy Boys.
    Heutinck L; Kampen NV; Jansen M; Groot IJ
    J Child Neurol; 2017 Apr; 32(5):450-457. PubMed ID: 28112012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
    Mercuri E; Signorovitch JE; Swallow E; Song J; Ward SJ; ;
    Neuromuscul Disord; 2016 Sep; 26(9):576-83. PubMed ID: 27423700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ambulatory capacity in Japanese patients with Duchenne muscular dystrophy.
    Awano H; Itoh C; Takeshima Y; Lee T; Matsumoto M; Kida A; Kaise T; Suzuki T; Matsuo M
    Brain Dev; 2018 Jun; 40(6):465-472. PubMed ID: 29551259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Evaluation of Muscle Composition Using Magnetic Resonance in 4 Boys With Duchenne Muscular Dystrophy: Case Series.
    Senesac CR; Lott DJ; Forbes SC; Mathur S; Arpan I; Senesac ES; Walter GA; Vandenborne K
    Phys Ther; 2015 Jul; 95(7):978-88. PubMed ID: 25592189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
    Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
    Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.